IPF Clinical Trial - Turkish Validity & Reliability of SGRQ-I

Status Recruiting

Clinical Trial Summary

The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary fibrosis patients, is not available. There is no commonly used quality of life questionnaire in patients with idiopathic pulmonary fibrosis. The aim of the study is to translate and validate the SGRQ idiopathic pulmonary fibrosis version of questionnaire into Turkish.

Clinical Trial Description

- The study is a cross-sectional, questionnaire validation study. - It is planned to complete the study within 2 years after the sufficient sample size is reached and the evaluations are made. The study will be terminated when the sufficient number of patients is reached. - The main thing in the application of special tools such as questionnaires is to prove the usability of the tool in the sample group to which it will be applied. The first step for this is the translation phase from the original language to the other language. At this stage, it is ideal for people who know the structure of the target language and the original language well, who have a good command of these languages and who are experienced in doing the translation. In our study, two people who are fluent in the original language will translate the questionnaire into the target language and two different people will translate the original language again. - To the participants; Demographic Evaluation Form, Saint George's Respiratory Questionnaire (SGRQ), and SGRQ idiopathic pulmonary fibrosis version of Questionnaire (SGRQ-I) will be applied. The SGRQ-I questionnaire will be administered again one week after the first application date in order to determine the test-retest reliability. - Scale reliability will be tested with Cronbach Alpha.For construct validity, confirmatory factor analysis will be applied and confirmatory factor analysis will be applied. For content validity, opinions of different experts will be taken for each item, and the status of items in the scale will be determined according to the results obtained by substituting it. In the logical validity process; Coverage of the components constituting the measured skill for each item will be considered. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05147597
Study type	Observational
Source	Saglik Bilimleri Universitesi
Contact	ESRA PEHLIVAN, Assoc.Prof.
Phone	02164189616
Email	fztesrakambur@yahoo.com
Status	Recruiting
Phase
Start date	January 9, 2022
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05570058` - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis	Phase 2
Recruiting	`NCT02807025` - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases	N/A
Recruiting	`NCT05895565` - A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects	Phase 1
Completed	`NCT03211507` - Idiopathic Pulmonary Fibrosis Job Exposures Study
Completed	`NCT02503657` - Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Recruiting	`NCT03873298` - Inhaled NO in IPF and COPD During 6 Minute Walk Test	Phase 2
Terminated	`NCT03864328` - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF	Phase 2
Completed	`NCT05803850` - A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058	Phase 1
Withdrawn	`NCT05349760` - A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT01266317` - Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations	Phase 1/Phase 2
Completed	`NCT04503044` - ILAs in CT Lung Cancer Screening Population
Recruiting	`NCT04564183` - Advancing Prevention of Pulmonary Fibrosis
Recruiting	`NCT05190211` - Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis	N/A
Recruiting	`NCT04263727` - A Study of Patients With Chronic Disease
Completed	`NCT05353556` - Effects of Home-based Inspiratory Muscle Training in Patients With IPF	N/A
Completed	`NCT02976935` - Functional MR Lung Imaging Using Hyperpolarised 129Xe
Recruiting	`NCT05193136` - Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
Recruiting	`NCT06181370` - Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF	Phase 1
Not yet recruiting	`NCT02885961` - The Coagulation Cascade in Idiopathic Pulmonary Fibrosis	N/A
Completed	`NCT02151435` - Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Turkish Validity and Reliability of SGRQ-I

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms